ATE254454T1 - Vorbeugung und behandlung von kachexie und anorexie - Google Patents

Vorbeugung und behandlung von kachexie und anorexie

Info

Publication number
ATE254454T1
ATE254454T1 AT97921367T AT97921367T ATE254454T1 AT E254454 T1 ATE254454 T1 AT E254454T1 AT 97921367 T AT97921367 T AT 97921367T AT 97921367 T AT97921367 T AT 97921367T AT E254454 T1 ATE254454 T1 AT E254454T1
Authority
AT
Austria
Prior art keywords
fatty acids
anorexia
cachexia
vitamin
source
Prior art date
Application number
AT97921367T
Other languages
English (en)
Inventor
Bonnie Chandler Abbruzzese
Mark Anthony Mccamish
Frederick Oliver Cope
Stephen Joseph Demichele
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27092312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE254454(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE254454T1 publication Critical patent/ATE254454T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00—Food or edible material: processes, compositions, and products
    • Y10S426/80—Geriatric
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00—Food or edible material: processes, compositions, and products
    • Y10S426/801—Pediatric

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Threshing Machine Elements (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Basic Packing Technique (AREA)
  • Recrystallisation Techniques (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT97921367T 1996-04-25 1997-04-25 Vorbeugung und behandlung von kachexie und anorexie ATE254454T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63517996A 1996-04-25 1996-04-25
US08/842,454 US6077828A (en) 1996-04-25 1997-04-24 Method for the prevention and treatment of cachexia and anorexia
PCT/US1997/006897 WO1997039749A2 (en) 1996-04-25 1997-04-25 Method for the prevention and treatment of cachexia and anorexia

Publications (1)

Publication Number Publication Date
ATE254454T1 true ATE254454T1 (de) 2003-12-15

Family

ID=27092312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921367T ATE254454T1 (de) 1996-04-25 1997-04-25 Vorbeugung und behandlung von kachexie und anorexie

Country Status (12)

Country Link
US (6) US6077828A (de)
EP (2) EP1415650A1 (de)
JP (1) JPH11508282A (de)
AT (1) ATE254454T1 (de)
AU (1) AU716532B2 (de)
CA (1) CA2252513C (de)
DE (1) DE69726280T2 (de)
DK (1) DK0914111T3 (de)
ES (1) ES2210523T3 (de)
NZ (1) NZ332291A (de)
PT (1) PT914111E (de)
WO (1) WO1997039749A2 (de)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203006A1 (en) * 1997-10-29 2003-10-30 Ajinomoto Co. Inc. Immunomodulator
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
US6013665A (en) * 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
US6130244A (en) * 1998-02-25 2000-10-10 Abbott Laboratories Product and method to reduce stress induced immune suppression
IT1299161B1 (it) * 1998-04-17 2000-02-29 Sigma Tau Healthscience Spa Composizione comprendente l-carnitina o un'alcanoil l-carnitina e nadh e/o nadph
ES2187115T3 (es) * 1999-01-20 2003-05-16 Nutricia Nv Preparado para lactantes.
US20050037065A1 (en) * 1999-05-27 2005-02-17 Drugtech Corporation Nutritional formulations
WO2000072831A1 (en) * 1999-05-27 2000-12-07 Drugtech Corporation Nutritional formulations
US6340705B1 (en) 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
US6228367B1 (en) * 1999-12-22 2001-05-08 Renew Life, Inc. Food supplement formulation
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
PT1317272E (pt) * 2000-05-25 2006-06-30 Boehringer Ingelheim Int Composicao para melhoramento da proteccao celular compreendendo um antioxidante lipofilo e um antioxidante hidrofilo
US6592863B2 (en) * 2000-08-22 2003-07-15 Nestec S.A. Nutritional composition
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
DE60140141D1 (de) * 2000-11-14 2009-11-19 Vital Health Sciences Pty Ltd Zusammensetzungen umfassend Komplexe von Tocopherolphosphatderivaten
JPWO2002040014A1 (ja) * 2000-11-16 2004-03-18 森永乳業株式会社 経口用又は経腸用の油脂組成物及びヘキサコサン酸低下剤
GB0028268D0 (en) * 2000-11-20 2001-01-03 Norske Stats Oljeselskap Well treatment
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
CA2439293A1 (en) * 2001-03-05 2002-09-12 Stephen P. Ernest Enteral formulation
US20040121044A1 (en) * 2001-03-14 2004-06-24 John Tiano Nutritional product with high protein, low carbohydrate content and good physical stability
BR0211673A (pt) 2001-07-27 2004-07-13 Vital Health Sciences Pty Ltd Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons
ATE487456T1 (de) * 2001-12-13 2010-11-15 Vital Health Sciences Pty Ltd Transdermaler transport von verbindungen
US6979457B2 (en) * 2001-12-28 2005-12-27 Renew Life Formulas, Inc. Food supplement formulation
GB0202900D0 (en) 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
NZ535549A (en) * 2002-03-08 2006-02-24 Monsanto Technology Llc Treatment and prevention of inflammatory disorders
FR2839887A1 (fr) * 2002-05-22 2003-11-28 Synergia Nouvelles compositions nutraceutiques et pharmaceutiques et leurs utilisations
US7273607B2 (en) * 2002-07-01 2007-09-25 Karl G. Schakel, legal representative Health enhancement method
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
GB0221480D0 (en) * 2002-09-16 2002-10-23 Laxdale Ltd Treatment of anorexia nervosa (AN) and bulimia
RU2335927C2 (ru) * 2002-09-20 2008-10-20 Новартис Аг Обогащенные лейцином питательные композиции
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
ATE430802T1 (de) 2003-08-21 2009-05-15 Monsanto Technology Llc Fettsäuredesaturasen aus primula
DE602004016385D1 (de) 2003-12-24 2008-10-16 Nutricia Nv Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
US7175864B1 (en) 2004-02-19 2007-02-13 Owades Joseph L Process for producing a malt beverage having improved foaming properties and product produced therefrom
JP4847437B2 (ja) * 2004-03-03 2011-12-28 バイタル ヘルス サイエンシズ プロプライアタリー リミティド アルカロイド製剤
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2005110124A1 (en) * 2004-04-15 2005-11-24 Abbott Laboratories Composition and methods for nutritional management of patients with hepatic disease
BRPI0509944A (pt) 2004-04-16 2007-09-25 Monsanto Technology Llc expressão de dessaturases de ácido graxo em milho
US8663679B2 (en) * 2004-04-29 2014-03-04 Abbott Laboratories Compositions for improving breast health in women
FR2869764B1 (fr) * 2004-05-07 2006-07-21 Olivier Roche Complement nutrionnel liquide et procede de preparation de ce complement
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
ATE464883T1 (de) * 2004-07-22 2010-05-15 Bend Res Inc Geschmacksabdeckende formulierung mit einer retardierten wirkstoffformulierung und/oder schnell löslichem cyclodextrin
BRPI0513673B8 (pt) * 2004-08-03 2021-07-27 Vital Health Sciences Pty Ltd método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
ES2397085T3 (es) * 2005-03-08 2013-03-04 Mitsui Norin Co., Ltd Procedimientos y combinaciones de polifenol-coxib
FR2882896B1 (fr) * 2005-03-14 2007-05-04 Larena Sa Composition alimentaire pour prevenir le syndrome de fragilite chez les personnes agees
US20090117197A1 (en) * 2005-03-21 2009-05-07 Vicus Therapeutics Llc Compositions and methods for ameliorating cachexia
US8128978B2 (en) 2005-06-10 2012-03-06 Calpis Co., Ltd. Method for preventing off-flavor in beverage composition
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US9179702B2 (en) * 2005-07-13 2015-11-10 Abbott Laboratories Liquid nutritional compositions containing unsaturated fatty acids
US20070031538A1 (en) * 2005-07-13 2007-02-08 Gul Konuklar Liquid nutritional compositions containing n-3 polyunsaturated fatty acids
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
US8329646B2 (en) * 2005-11-30 2012-12-11 Nestec S.A. Methods for the treatment of muscle loss
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
ZA200805905B (en) * 2005-12-16 2009-10-28 Nutricia Nv Use of soluble dietary fibres against muscle wasting
JP5227182B2 (ja) 2005-12-19 2013-07-03 アボット・ラボラトリーズ １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用
WO2007070981A1 (en) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
CA2673940C (en) * 2007-01-03 2015-11-03 Monsanto Technology Llc Food compositions incorporating additional long chain fatty acids
AU2008203870B2 (en) * 2007-01-03 2013-08-22 Monsanto Technology, Llc Food compositions incorporating stearidonic acid.
WO2008100220A1 (en) * 2007-02-14 2008-08-21 Karolinska Innovations Ab Compositions for increasing body weight, use and methods
NZ555163A (en) * 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
EP2025248A1 (de) * 2007-07-31 2009-02-18 Fresenius Kabi Deutschland GmbH Zubehör zur Verhinderung von Abmagerungen
US20090110800A1 (en) * 2007-10-24 2009-04-30 Wilkes Richard S Food compositions incorporating additional long chain fatty acids
US20100291267A1 (en) * 2007-11-29 2010-11-18 Monsanto Technology Llc Meat products with increased levels of beneficial fatty acids
US20090169650A1 (en) * 2008-01-02 2009-07-02 Wilkes Richard S Food compositions incorporating stearidonic acid
WO2009087988A1 (ja) 2008-01-09 2009-07-16 Nutri Co., Ltd. がん化学療法時に起こる酸化ストレス及び／又は副作用の軽減あるいはがん化学療法時の栄養状態を改善するための組成物
JP5527986B2 (ja) * 2008-02-19 2014-06-25 株式会社アーネストメディスン 医薬組成物
KR101325374B1 (ko) 2008-02-19 2013-11-08 가부시키가이샤 오츠까 세이야꾸 고죠 신체 기능의 회복에 유용한 경구 또는 경장 조성물
US20100003350A1 (en) * 2008-06-26 2010-01-07 Ryaoma, Inc. Composition possessing antioxidant, immonomodulated, and antitumorous action and method of treating neoplasms
CA2843880A1 (en) * 2008-07-07 2010-01-14 Pentec Health, Inc. Nutritive compositions and methods of using same
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US20100069288A1 (en) * 2008-09-12 2010-03-18 Wulf Droge Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival
WO2010049142A1 (de) * 2008-10-29 2010-05-06 Lipid4Life Gmbh Ernährungszusammensetzung enthaltend omega- 3 -fettsäuren und mct
EP2374452B1 (de) * 2008-12-05 2019-07-24 Ajinomoto Co., Inc. Nährstoffzusammensetzung
US8060617B2 (en) * 2008-12-19 2011-11-15 Cisco Technology, Inc. Reserving network resources during scheduling of meeting event
BRPI1014923A2 (pt) * 2009-04-01 2015-09-01 Nestec Sa Redução do risco de obesidade
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2016219657B2 (en) * 2009-04-29 2018-02-01 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
WO2010137944A1 (en) * 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
IT1395408B1 (it) * 2009-08-31 2012-09-14 Cangiano Formulazione farmaceutica a base di aminoacidi a catena ramificata per la cura della sindrome anoressia nausea e vomito (sanv) da chemioterapici
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ601027A (en) * 2010-01-04 2014-08-29 Pentec Health Inc Nutritive compositions and methods of using same
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
BR112012018174A2 (pt) 2010-01-29 2019-08-27 Abbott Lab líquidos nutricionais embalados assepticamente compreendendo hmb.
ES2481865T3 (es) 2010-01-29 2014-07-31 Abbott Laboratories Emulsiones nutricionales que comprenden HMB de calcio
EP2531047B1 (de) 2010-02-05 2024-11-13 Phosphagenics Limited Träger mit einem nichtneutralisierten tocopherylphosphat
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
JP2013528800A (ja) * 2010-05-12 2013-07-11 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド ネコの炎症を診断、抑制および予防し、炎症状態を緩和するための方法
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
KR101919747B1 (ko) * 2011-02-17 2018-11-20 각꼬호우진 구루메 다이가쿠 화학요법제의 항종양 활성 증강제
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
CN103458890A (zh) * 2011-04-12 2013-12-18 雀巢产品技术援助有限公司 包括支链脂肪酸的营养组合物及其使用方法
WO2012141316A1 (ja) 2011-04-13 2012-10-18 味の素株式会社 栄養組成物
WO2012141575A1 (en) 2011-04-14 2012-10-18 N.V.Nutricia Combination of epa, dpa and/or dha with a chemotherapeutic agent
US10682327B2 (en) * 2011-04-17 2020-06-16 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US20210176999A1 (en) 2011-04-17 2021-06-17 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US10653160B2 (en) * 2011-04-17 2020-05-19 Omega Foods, LLC Prepared foods having high efficacy omega 6/omega 3 balanced polyunsaturated fatty acids
US8691293B2 (en) * 2011-04-17 2014-04-08 Omega Foods, LLC Low inflammatory blended oils
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (de) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Verfahren zur behandlung von hypertriglyceridämie
EP2790522B1 (de) 2011-12-14 2015-06-03 Nestec S.A. Emulgiertes lebensmittelprodukt mit milchprotein
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
EP2846779A4 (de) 2012-05-07 2015-12-16 Omthera Pharmaceuticals Inc Zusammensetzungen aus statinen und omega-3-fettsäuren
EP4338805B1 (de) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaensäureethylester zur verwendung bei der verringerung des risikos eines nicht-fatalen herzinfarktes bei einer person in statin-therapie
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
EP2977047B1 (de) 2013-02-26 2022-10-19 Ajinomoto Co., Inc. Nährmittelzusammensetzung
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CN103652926A (zh) * 2013-12-30 2014-03-26 上海仙普生物科技有限公司 肿瘤病人食品组合物
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
CN107041897A (zh) * 2016-02-05 2017-08-15 大汉酵素生物科技股份有限公司 一种用以制备改善恶病质的组合物及其制备方法
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP7123945B2 (ja) 2016-10-03 2022-08-23 シャー，ホウン・サイモン がん放射線療法を増強するための組成物および方法
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US12029765B2 (en) 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer
JP7788129B2 (ja) * 2017-06-13 2025-12-18 シャー，ホウン・サイモン 癌化学療法を増強するための組成物および方法
US10905724B2 (en) 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing hyperthermia therapy
JP7336993B2 (ja) 2017-06-13 2023-09-01 シャー，ホウン・サイモン 癌放射線療法を増強する組成物および方法
US11285124B2 (en) 2017-08-18 2022-03-29 Calwood Nutritionals, Llc Compositions and methods for increasing muscle mass and strength, treating skin, reducing wear and degradation from aging and exposure and improving recovery from stress such as exercise and trauma
US11147761B2 (en) * 2018-01-12 2021-10-19 Nicole Akmenkalns Topical supplement composition and method of use
MY202355A (en) * 2018-03-01 2024-04-24 463Ip Partners Llc Microencapsulated products, clear solutions thereof, and methods of making
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN108812934A (zh) * 2018-05-31 2018-11-16 四川省丹丹郫县豆瓣集团股份有限公司 一种高不饱和脂肪酸调和油及其制备方法
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
WO2021086172A1 (en) * 2019-10-31 2021-05-06 N.V. Nutricia Composition comprising epa, ma and leucine for improving muscle function
CN110812455A (zh) * 2019-11-01 2020-02-21 葵花药业集团北京药物研究院有限公司 一种治疗儿童厌食、偏食等病症的液体口服制剂及其制备方法和用途
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPS60133094A (ja) * 1983-12-21 1985-07-16 日清製油株式会社 高純度エイコサペンタエン酸の製造法
US5053387A (en) * 1987-02-20 1991-10-01 Shriners Hospitals For Crippled Children Omega-3 fatty acids in traumatic injury treatment
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
ES2052066T3 (es) * 1988-10-31 1994-07-01 Sandoz Nutrition Ltd Mejoras en o relacionadas con compuestos organicos.
US5231085A (en) * 1988-10-31 1993-07-27 Sandoz Ltd. Compositions and methods for the enhancement of host defense mechanisms
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5330972A (en) * 1993-05-28 1994-07-19 Abbott Laboratories Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus
US5393784A (en) * 1993-07-21 1995-02-28 New York State Office Of Mental Health Treatment of tardive dyskinesia with leucine, isoleucine, valine or mixtures thereof
AU7787194A (en) * 1993-09-23 1995-04-10 Ali Altunkaya Composition containing omega 3 and/or omega 6 polyunsaturated acids having from 12 to 22 carbon atoms
US5444054A (en) * 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis
US5599835A (en) * 1994-11-23 1997-02-04 Fischer; Frederick B. Use of DL-lipoic acid as a medical food in the treatment of diabetes mellitus
DE19528461A1 (de) * 1995-08-03 1997-02-06 Braun Melsungen Ag Präparat zur Ernährung
US5776913A (en) * 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma

Also Published As

Publication number Publication date
WO1997039749A3 (en) 1997-12-04
DE69726280D1 (de) 2003-12-24
EP1415650A1 (de) 2004-05-06
NZ332291A (en) 2000-07-28
US6326355B1 (en) 2001-12-04
PT914111E (pt) 2004-04-30
WO1997039749A2 (en) 1997-10-30
AU716532B2 (en) 2000-02-24
EP0914111A2 (de) 1999-05-12
US20020099020A1 (en) 2002-07-25
HK1019857A1 (en) 2000-03-03
ES2210523T3 (es) 2004-07-01
US7223736B2 (en) 2007-05-29
DK0914111T3 (da) 2004-03-29
DE69726280T2 (de) 2004-09-02
JPH11508282A (ja) 1999-07-21
US6387883B1 (en) 2002-05-14
AU2742497A (en) 1997-11-12
US6077828A (en) 2000-06-20
US20070196445A1 (en) 2007-08-23
EP0914111B1 (de) 2003-11-19
CA2252513C (en) 2002-11-19
CA2252513A1 (en) 1997-10-30
US20040167081A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
ATE254454T1 (de) Vorbeugung und behandlung von kachexie und anorexie
ZA867387B (en) Pharmaceutical and dietary composition
FR2715582B1 (fr) Microcapsules à paroi de flavonoïde réticulée et compositions en contenant.
CA2128899A1 (en) Antioxidant System for Powdered Nutritional Products
ZA894380B (en) Essential fatty acid compositions
FR2714600B1 (fr) Composition protectrice, nutritive et/ou raffermissante pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation.
EP1787532A3 (de) Gemische von mikrobiellen Ölen und deren Verwendungen
ATE212194T1 (de) Nahrungsprodukt zur behandlung der ulzerativen kolitis sowie verwendung desselben
DK0693278T3 (da) Kombinationer af vasoaktive stoffer med fedtsyrer for at forebygge tab af hår
MXPA03005434A (es) Aceites para la piel compuestos de constituyentes solubles en aceite y w/o emulsificadores con un valor hlb entre 2 y 6 opcionalmente al menos un aditivo estandar, y metodo para su fabricacion y uso.
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
AU1489688A (en) Omega-3 fatty acids in traumatic injury treatment
CA2077628A1 (en) Composition of natural antioxidants for the stabilization of polyunsaturated oils
ATE110274T1 (de) Mittel zur verbesserung spezifischer eigenschaften des blutes.
EP0764438A3 (de) Mittel zur dauerhaften Verformung von menschlichen Haaren
NO975074L (no) Preparater
ATE214922T1 (de) Antioxydationwirkung von 3-dehydroshikimaten
ATE235249T1 (de) Die von morphogenen peptiden hervorgerufene wiederherstellung von gewebe aus sinneszellen
EP0539516A4 (de)
UA10906C2 (uk) Препарат для профілактики і лікуваhhя авітаміhозів сільськогосподарських твариh та птиці
RU93055059A (ru) Способ создания модели эвентрации у крыс
MX9605053A (es) Proceso de micelizacion de nutrientes para ser absorbidos por el cuerpo humano.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914111

Country of ref document: EP